E.V.S. Subrahmanyam

A new series of novel substituted Gallic acid derivatives were synthesized by reacting methylated Gallic acid with hydrazine hydrate and then with various substituted aromatic aldehyde in mild and facile synthetic route to form various Schiff base derivatives.  Melting points of the synthesized compounds were determined by open capillary and are uncorrected. The purity of the compounds was checked using precoated TLC plates (MERCK, 60F) using chloroform: methanol (8:2) solvent system. The developed chromatographic plates were visualized under UV at 254nm. IR spectra were recorded using KBr on Josco FTIR model 8400 spectrophotometer, 1H NMR spectra in DMSO on a BRUKER FT-NMR instrument using TMS as internal standard. FAB mass spectra were recorded on JEOL SX 102 (DA-6000 mass Spectrometer) Data system using Argon (6KV.10MA) as the FAB gas. The designed compounds were screened for Antibacterial activity against Staphylococcus aureus and Escherichia coli and Antifungal activity against Aspergillus Niger in comparison with Ofloxacin and Fluconazole as standard to reveal the potency of synthesized derivatives. In accordance with the data obtained from antimicrobial activity, all the synthesized Schiff bases of substituted gallic acid have shown good activity against the tested microbes. Among these Schiff bases, compound bearing p-chloro group, o-chloro group, p-nitro group and m-nitro group has shown good activity against all the tested bacteria and fungi.

  Pharmaceutical supply chain has always been a point of great interest in academic research as well as in industrial practice. However this popular buzzword still remains an ill-defined and poorly understood concept and this will provide a better understanding of the different levels of pharmaceutical supply chain issues and the terms regarding supply chain for pharmaceuticals. Though the pharmaceutical industry has grown by leaps and bounds the risk affecting it has also increased proportionately. Furthermore this addresses the issues of risk mitigation in pharmaceutical supply chain by providing quantified empirical results. Based on the available literature four major risks affecting the pharmaceutical supply chain were identified as regulatory risk, inventory risk, counterfeit risk and financial risk. Ranking and management strategies of these are based on Analytical Hierarchy Process model. Also solutions to these risks are provided based on the results of the survey questionnaires and literature study which would be best suited for the industry to flourish and survive in today’s competitive global marketplace.